Peter  Altman net worth and biography

Peter Altman Biography and Net Worth

CEO of BioCardia
Dr. Altman has served as our President and CEO since 2002. He was CEO (1999 to 2003) and board member (1999 to 2014) of CareDx (NASDAQ: CDNA), a developer of a gene-based diagnostics for cardiac and other organ transplantation. He was CEO for Lumen Therapeutics from 2004 to 2005, an early-stage pharmaceutical company. He has extensive experience in life science research and product development, is named inventor in 45 U.S. patents, and has authored 40 scientific publications. Dr. Altman currently serves as a director on the board of Oncocyclist Biotech. He received his Ph.D. in Bioengineering/Pharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley, his Management of Technology certificate from the Walter A. Haas School of Business at the University of California, Berkeley, and both his Master of Science and Bachelor of Science in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Dr. Altman has been elected Fellow of the American Heart Association.

What is Peter Altman's net worth?

The estimated net worth of Peter Altman is at least $230,202.00 as of April 3rd, 2025. Dr. Altman owns 109,620 shares of BioCardia stock worth more than $230,202 as of April 4th. This net worth evaluation does not reflect any other assets that Dr. Altman may own. Additionally, Dr. Altman receives an annual salary of $515,510.00 as CEO at BioCardia. Learn More about Peter Altman's net worth.

How old is Peter Altman?

Dr. Altman is currently 57 years old. There are 2 older executives and no younger executives at BioCardia. Learn More on Peter Altman's age.

What is Peter Altman's salary?

As the CEO of BioCardia, Inc., Dr. Altman earns $515,510.00 per year. Learn More on Peter Altman's salary.

How do I contact Peter Altman?

The corporate mailing address for Dr. Altman and other BioCardia executives is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. BioCardia can also be reached via phone at (650) 226-0120 and via email at investors@biocardia.com. Learn More on Peter Altman's contact information.

Has Peter Altman been buying or selling shares of BioCardia?

During the last quarter, Peter Altman has bought $2,688.00 in BioCardia stock. Most recently, on Thursday, April 3rd, Peter Altman bought 1,200 shares of BioCardia stock. The stock was acquired at an average cost of $2.24 per share, with a total value of $2,688.00. Following the completion of the transaction, the chief executive officer now directly owns 109,620 shares of the company's stock, valued at $245,548.80. Learn More on Peter Altman's trading history.

Are insiders buying or selling shares of BioCardia?

In the last twelve months, BioCardia insiders bought shares 15 times. They purchased a total of 31,836 shares worth more than $75,646.05. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 3,257 shares worth more than $6,514.00. The most recent insider tranaction occured on April, 3rd when CEO Peter Altman bought 1,200 shares worth more than $2,688.00. Insiders at BioCardia own 20.0% of the company. Learn More about insider trades at BioCardia.

Information on this page was last updated on 4/3/2025.

Peter Altman Insider Trading History at BioCardia

Peter Altman Buying and Selling Activity at BioCardia

This chart shows Peter Altman's buying and selling at BioCardia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$2.69kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40k-$20k$0$20k$40kTotal Insider BuyingTotal Insider Selling

BioCardia Company Overview

BioCardia logo
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Read More

Today's Range

Now: $2.10
Low: $2.04
High: $2.24

50 Day Range

MA: $2.47
Low: $2.01
High: $2.84

2 Week Range

Now: $2.10
Low: $1.63
High: $6.15

Volume

49,135 shs

Average Volume

277,492 shs

Market Capitalization

$9.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28